Trial Spark, which wants to use its clinical trials management software in drug discovery, discontinued $ 156M Series C earlier this year for $ 1B + (Emma Court / Bloomberg)


Emma Court / Bloomberg:

Trial Spark, which wants to use its clinical trials management software in drug discovery, discontinued the $ 156M Series C to $ 1B + earlier this year.– – The trial spans from spark clinical trials to developing drugs – The company raised 6 156 million, valued at more than 1 billion

Leave a Reply

Your email address will not be published.